Revitalizing Innovation: The Impact of UK Medic...

By João L. Carapinha

June 6, 2025

The UK Medicine Payment Rates for pharmaceuticals, stipulated under the Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), have reached an alarming 23.5% in 2025. This policy, intended to limit NHS spending on branded medic...
Blinatumomab Benefit Assessment for ALL and Health Economics
Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges
NICE HealthTech Reforms: Accelerating Digital Innovation in NHS and Global He...
Tolebrutinib MS Analysis: Evaluating Economic Impact in SPMS
NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment...
EU Establishes Expert Panel for Orphan Paediatric Devices
High Orphan Drug Prices Persist Despite Market Exclusivity Expiration
Biosimilars Price Competition: Impact on U.S. Pharmaceutical Pricing and Mark...
Hepatitis C Investment Impact: Maximizing Health and Economic Returns in China
First At-Home HPV Testing Approval: FDA Clears Teal Wand
MR-107A-02: Revolutionizing Non-Opioid Pain Management with Viatris’ Breakthr...
Bulevirtide HDV Therapy: Promising Results in Durable Virologic Control